Genmab — April 2018
-
Men hvorfor skulle BMS starte disse store opdivo / dara studier hvis de ikke ville noget med dem?
-
Hvis udfaldet på opdivo / dara studier er positive, og BMS alligevel skulle droppe at gå i fase 3 af hensyn til deres involvering i NKTR-214, så kan Janssen da bare køre disse fase 3 studier.
-
The Novartis deal to buy AveXis today, is apparantly also a road into CAR-T https://www.bloomberg.com/news/articles/2018-04-09/novartis-to-pay-8-7-billion-for-gene-therapy-company-avexis https://www.fiercebiotech.com/biotech/novartis-inks-8-7b-avexis-buyout-to-build-gene-therapy-unit
-
Deutsche Bank spår dara salg i Q1 til USD 425 mill. (konsensus er USD 406 mill.)
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind